Arcellx Trading Volume Surges to $300M Ranks 426th Amid Post-Gilead Acquisition Regulatory Crossroads

Market Snapshot

On March 10, 2026, Arcellx (NASDAQ:ACLX) closed with a 0.10% decline, marking a modest pullback in its stock price. Despite the drop, the company’s trading volume surged by 82.55% compared to the previous day, reaching $0.30 billion. This elevated volume ranked Arcellx 426th among all stocks traded that day, indicating heightened investor interest. The performance contrasts sharply with the 77.9% rally in early February 2026, when Gilead Sciences announced a $7.8 billion acquisition deal for the biotech firm.

Key Drivers

The recent decline in Arcellx’s stock price, though minor, follows a period of extraordinary volatility linked to the landmark acquisition by Gilead Sciences. In February 2026, Gilead agreed to acquire Arcellx for $115 per share in cash, a 79% premium over its pre-announcement closing price. This deal, valued at up to $7.8 billion, represented Gilead’s largest acquisition since its $21 billion purchase of Immunomedics in 2020. The transaction was driven by Gilead’s strategic push to diversify beyond its HIV and liver disease therapies, particularly amid declining revenues from its flagship drug Veklury and looming patent expirations.

A critical factor underpinning the acquisition is Arcellx’s investigational CAR-T therapy, anito-cel, developed in collaboration with Kite Pharma. This treatment targets multiple myeloma and is under FDA review as a fourth-line therapy, with a decision scheduled for December 23, 2026. Analysts, including RBC Capital Markets’ Brian Abrahams, have highlighted anito-cel’s potential to outperform existing therapies like Carvykti (developed by Johnson & Johnson and Legend Biotech) due to its favorable safety profile. However, the pending regulatory outcome introduces uncertainty, as the FDA’s approval could significantly influence the deal’s long-term value for Gilead and Arcellx shareholders.

Gilead’s acquisition strategy reflects broader industry trends, with the biopharma giant actively seeking partnerships and acquisitions to bolster its oncology pipeline. CEO Daniel O’Day has emphasized expanding into cell therapy and other high-growth areas to offset vulnerabilities in its core businesses. The Arcellx deal aligns with this vision, providing Gilead access to cutting-edge immunotherapy platforms and enhancing its position in the competitive CAR-T market. Nonetheless, the transaction’s completion is not expected until the second quarter of 2026, leaving room for market fluctuations or regulatory hurdles to impact investor sentiment in the interim.

The recent 0.10% dip in Arcellx’s stock price may also be attributed to broader market dynamics, including sector-specific corrections following the sharp rally in early February. While the acquisition premium initially drove strong investor optimism, the subsequent pullback suggests profit-taking or caution as the market digests the deal’s implications. Additionally, the news articles note that some analysts have shifted focus to AI stocks, which are perceived as offering higher growth potential with lower downside risk. This comparative analysis, though not directly tied to Arcellx’s fundamentals, could indirectly influence portfolio allocations and market sentiment toward biotech stocks.

In summary, Arcellx’s stock performance is inextricably linked to the Gilead acquisition and the regulatory trajectory of anito-cel. While the deal provides a clear floor for the stock’s valuation, the absence of immediate catalysts and the pending FDA decision create a mixed outlook. Investors are likely balancing the long-term benefits of the acquisition with near-term uncertainties, resulting in the current modest decline. As the FDA decision date approaches in late 2026, the market’s focus will shift to whether anito-cel meets its regulatory milestones, which could reignite interest in the stock or reinforce caution.